GlassScriptPhysician profile
Peter S Mckay
NPI 1235163361
$2,969.56
in general payments reported to CMS, 2019-2025
25 companies · $284 in 2025
The $284 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $976 · 2020: $380 · 2021: $136 · 2022: $284 · 2023: $221 · 2024: $688 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,193.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $590.44 | 2019-2025 | Clareon, Tryptyr, Argos |
| Abbvie INC. | $507.13 | 2022-2025 | |
| Kala Pharmaceuticals, INC. | $216.72 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $193.19 | 2019-2023 | |
| Allergan, INC. | $177.25 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $145.59 | 2019-2025 | |
| Sight Sciences, INC. | $144.35 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $136.49 | 2019-2020 | |
| Amgen INC. | $131.12 | 2024-2025 | Tepezza |
| Bausch & Lomb Americas INC. | $117.93 | 2024-2025 | Miebo, Xiidra |
| Hoffmann-La Roche Limited | $108.69 | 2019 | |
| Oyster Point Pharma, INC. | $84.48 | 2022-2025 | Tyrvaya, Ryzumvi |
| Dompe US, INC. | $72.96 | 2020-2025 | Oxervate |
| Ocular Therapeutix, INC. | $68.15 | 2022-2025 | Dextenza |
| Carl Zeiss Meditec Ag | $38.80 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $36.30 | 2019 | |
| Astellas Pharma US INC | $35.97 | 2023 | |
| Horizon Therapeutics Plc | $32.71 | 2022-2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $27.47 | 2024 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $24.53 | 2019 | |
| Harrow Eye, LLC | $21.04 | 2023 | Vevye |
| Glaxosmithkline, LLC. | $19.31 | 2025 | Trelegy Ellipta |
| Omeros Corporation | $15.56 | 2019 | |
| Eyevance Pharmaceuticals LLC | $11.79 | 2022 | |
| Vyera Pharmaceuticals, LLC | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Mckay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.